Matthew Siegel is vice president of medical affairs at Maine Behavioral Healthcare in Portland.
Matthew Siegel
Vice president
Maine Behavioral Healthcare
From this contributor
Autism can mask anxiety symptoms
Anxiety is one of the most common mental health conditions, as well as one of the most treatable. But when a person has autism, anxiety symptoms can be hard to see. Matthew Siegel calls for anxiety tests and treatments that are tailored to people with autism.
Searching for psychiatrists with expertise in autism
There is an urgent need for psychiatrists who are trained to care for individuals with autism. Matthew Siegel calls for a formal training program in autism for psychiatrists.
Searching for psychiatrists with expertise in autism
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.